Highlights
- CVS Health and OptumRx announce formulary updates effective January 1, 2022
- White House reveals COVID-19 action plan
- Department of Health and Human Services (HHS) publishes “Comprehensive Plan for Addressing High Drug Prices”
- FDA authorizes booster doses of COVID-19 vaccine for certain populations
FDA Approvals and Launches
- Byooviz (ranibizumab-nuna) receives approval as a biosimilar to Lucentis (ranibizumab), the first ophthalmic biosimilar.
- Opzelura (ruxolitinib) cream receives approval as a topical treatment for atopic dermatitis.
- Qulipta (atogepant) receives approval to treat episodic migraines.
- Livmarli (maralixibat) receives approval to treat certain symptoms of Alagille syndrome, a rare liver disorder.
News
CVS Health and OptumRx announce formulary updates effective January 1, 2022
- 20 drugs will be excluded from the CVS formulary, two drugs will be added to Tier 1.
- CVS Health estimates that the formulary removals will not affect 99.61% of members.
- 20 drugs will be excluded from the OptumRx Premium Formulary, four drugs will be downtiered, and three drugs will be uptiered.
White House reveals COVID-19 action plan
- The plan includes an Occupational Safety and Health Administration (OSHA) rule mandating that all employers with 100 or more employees require employees to get vaccinated or produce negative COVID-19 test results on a weekly basis.
- The rule is not active as of October 2021 and is still in development.
Department of Health and Human Services (HHS) publishes “Comprehensive Plan for Addressing High Drug Prices”
- The report proposes potential legislation that includes drug pricing negotiation, Medicare Part D reform, policies that accelerate the use of biosimilar and generic drugs, and other possible policies.
FDA authorizes booster doses of COVID-19 vaccine for certain populations
- Appropriate populations include those 65 years of age or older and those with higher risk of severe disease or higher risk of exposure.
FiercePharma previews potential 2021 FDA approvals
- Potential approvals include efgartigimod, a first in-class treatment for autoimmune disorder myasthenia gravis.
ARS Pharmaceuticals takes steps to prepare for the launch of Neffy (epinephrine nasal spray)
- The manufacturer received Fast Track Designation for the drug in 2019, which is still pending FDA approval.
Bausch Health settles for $300 million in Glumetza (metformin ER) lawsuit
- The settlement is the result of an antitrust lawsuit, alleging that the manufacturer paid a competitor to delay the launch of a generic version of the product.
Eli Lilly reduces list price of generic insulins
- The pricing change will apply to all generic insulins produced by the manufacturer and will take effect on January 1, 2022, reducing the price 40%.
Clinical Trials
Pfizer begins phase 3 clinical trial for investigational vaccine against respiratory syncytial virus (RSV)
- The RENOIR trial will test the safety and efficacy of the vaccine in adults ages 60 years or older.
Explore more tags from this article
About the Author(s)
Contact us
We’re here to help you break through complex challenges and achieve next-level success.